We are live on ! Find out more
IMUC

ImmunoCellular Therapeutics, Ltd.
IMUC

Delisted

IMUC was delisted on the 16th of October, 2018.

Back to rankings

27 hedge funds and large institutions have $405K invested in ImmunoCellular Therapeutics, Ltd. in 2018 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more funds holding

Funds holding: 20 → 27 (+7)

13% less capital invested

Capital invested by funds: $464K → $405K (-$59K)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

Holders
27
Holders Change
+7
Holders Change %
+35%
% of All Funds
0.61%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
2
Reduced
4
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$30.7K
2
TSS
Two Sigma Securities
New York
+$14.2K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$7.57K
4
UBS Group
UBS Group
Switzerland
+$6.05K
5
NFG
Next Financial Group
Texas
+$691

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$15.3K
2
VF
Virtu Financial
New York
-$12.3K
3
Invesco
Invesco
Georgia
-$316
4
Morgan Stanley
Morgan Stanley
New York
-$6

IMUC Hedge Fund Activity: Q3 2018 in Review

27 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics, Ltd. (IMUC) for Q3 2018, worth a combined $405K — down 13% from $464K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new IMUC positions and 0 closed out — a net gain of 7 holders — while 2 added to existing stakes and 4 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $30.7K. The largest seller was Citadel Advisors, cutting an estimated $15.3K.

  • 27 institutional investors held ImmunoCellular Therapeutics, Ltd. (IMUC) as of Q3 2018, up from 20 in Q2 2018.
  • Funds reported $405K of ImmunoCellular Therapeutics, Ltd. stock for Q3 2018, down 13% quarter-over-quarter.
  • 7 funds opened new ImmunoCellular Therapeutics, Ltd. positions in Q3 2018 and 0 closed out, a net change of +7 holders.
  • The largest ImmunoCellular Therapeutics, Ltd. buyer in Q3 2018 was Renaissance Technologies, an estimated $30.7K added.
  • The largest ImmunoCellular Therapeutics, Ltd. seller in Q3 2018 was Citadel Advisors, an estimated $15.3K sold.

Based on aggregated 13F filings for Q3 2018.